See more : Touchstone Exploration Inc. (TXP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Aridis Pharmaceuticals, Inc. (ARDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aridis Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Luckwel Pharmaceuticals Inc. (LWEL) Income Statement Analysis – Financial Results
- Clínica Baviera, S.A. (CBAV.MC) Income Statement Analysis – Financial Results
- Entravision Communications Corporation (EVC) Income Statement Analysis – Financial Results
- Future plc (FUTR.L) Income Statement Analysis – Financial Results
- Sonagi, S.G.P.S., S.A. (SNG.LS) Income Statement Analysis – Financial Results
Aridis Pharmaceuticals, Inc. (ARDS)
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.00M | 1.02M | 2.76M | 860.00K | 2.27M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M |
| Gross Profit | 0.00 | 0.00 | 1.00M | 1.02M | 2.76M | 860.00K | 342.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 15.07% |
| Research & Development | 25.92M | 37.94M | 16.96M | 24.08M | 23.00M | 17.44M | 6.26M |
| General & Administrative | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.16M | 7.31M | 6.45M | 6.03M | 3.87M | 3.16M | 1.97M |
| Other Expenses | -3.09M | -1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.99M | 43.71M | 23.40M | 30.11M | 26.87M | 20.60M | 8.23M |
| Cost & Expenses | 29.99M | 43.71M | 23.40M | 30.11M | 26.87M | 20.60M | 10.15M |
| Interest Income | 0.00 | 0.00 | 77.00K | 357.00K | 0.00 | 234.00K | 0.00 |
| Interest Expense | 378.00K | -245.00K | 0.00 | 0.00 | 420.00K | 0.00 | 366.00K |
| Depreciation & Amortization | 487.00K | -722.00K | 337.00K | 338.00K | 283.00K | 62.00K | 23.00K |
| EBITDA | -29.51M | -44.43M | -22.06M | -28.75M | -23.83M | -19.68M | -7.86M |
| EBITDA Ratio | 0.00% | 0.00% | -2,240.10% | -2,846.09% | -933.95% | -1,688.84% | -338.87% |
| Operating Income | -29.99M | -43.71M | -22.40M | -29.09M | -24.12M | -19.74M | -7.88M |
| Operating Income Ratio | 0.00% | 0.00% | -2,240.10% | -2,846.09% | -874.76% | -2,295.12% | -347.47% |
| Total Other Income/Expenses | -378.00K | 1.52M | 68.00K | -594.00K | 2.01M | -4.92M | -538.00K |
| Income Before Tax | -30.37M | -43.19M | -22.33M | -29.68M | -22.11M | -24.66M | -8.42M |
| Income Before Tax Ratio | 0.00% | 0.00% | -2,233.30% | -2,904.21% | -801.78% | -2,866.98% | -371.18% |
| Income Tax Expense | 378.00K | -912.00K | -414.00K | -695.00K | 2.43M | 4.92M | 538.00K |
| Net Income | -30.75M | -42.28M | -21.92M | -28.99M | -22.11M | -24.66M | -8.42M |
| Net Income Ratio | 0.00% | 0.00% | -2,191.90% | -2,836.20% | -801.78% | -2,866.98% | -371.18% |
| EPS | -1.64 | -3.44 | -2.39 | -3.43 | -7.02 | -3.12 | -1.07 |
| EPS Diluted | -1.64 | -3.44 | -2.39 | -3.43 | -7.02 | -3.12 | -1.07 |
| Weighted Avg Shares Out | 18.78M | 12.29M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
| Weighted Avg Shares Out (Dil) | 18.78M | 12.29M | 9.17M | 8.46M | 3.15M | 7.89M | 7.89M |
Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)
Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update
Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded by Zacks Investment Research to “Hold”
Source: https://incomestatements.info
Category: Stock Reports